Novartis MS Therapy FTY720 Enters Phase III With Lower, Untested Dose
Executive Summary
Following delays due to FDA safety concerns, Novartis is moving forward with Phase III trials of its oral multiple sclerosis therapy FTY720, although one of the two doses being evaluated lacks clinical data to support its efficacy